Amarin (AMRN) Stock News

Amarin Corporation (NASDAQ:AMRN) has announced that data from the REDUCE-IT trial will be presented at the ACC.23/WCC in New Orleans, March 4-6, 2023. This includes research on the efficacy of VASCEPA/VAZKEPA (icosapent ethyl) in patients who recently experienced acute coronary syndrome. Key presentations include analyses on EPA and its role in cardiovascular risk reduction. Amarin's Chief Medical Officer highlighted that these findings enhance the understanding of icosapent ethyl's utility in treating high-risk cardiovascular patients and compared EPA's antioxidant effects against other oils. The conference will feature multiple presentations sharing critical insights on cardiovascular health.

Sarissa Capital Management accuses the Amarin board of bad faith for approving substantial equity grants to executives, including Karim Mikhail, just before a crucial proxy contest. The board awarded over 3.6 million shares, with Mikhail receiving 70% more than last year, despite the company's poor performance. Sarissa claims these grants circumvented fiduciary duties and lacked performance criteria, questioning the board's integrity during a contested election. They demand Mikhail return these grants to employees, arguing that board actions reflect ongoing mismanagement, jeopardizing shareholder interests. Sarissa aims to hold directors accountable and initiate board reform.

Amarin Corporation plc (NASDAQ:AMRN) announced its president and CEO, Karim Mikhail, will participate in the Cowen Annual Health Care Conference from March 6-8, 2023, in Boston. Mikhail's presentation is scheduled for March 8, 2023, at 1:30 p.m. ET. The conference will be available via live webcast, which will also be archived on the company’s website. Amarin is dedicated to advancing cardiovascular disease management through innovation and research, and they maintain a global presence with offices in the U.S., Ireland, and Switzerland.

Sarissa Capital Management LP urges Amarin Corporation plc (NASDAQ: AMRN) shareholders to vote in favor of board changes at the company. The call to action is aimed at removing Chairman Per Wold-Olsen, whom Sarissa accuses of causing significant value destruction due to operational failures. Sarissa, as the largest shareholder, emphasizes its commitment to creating value and has proposed qualified nominees for the board. Shareholders must submit their votes by midnight (New York Time) today to ensure they count for the upcoming meeting on February 28, 2023. More information can be found on Sarissa's proxy website.

Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on March 1, 2023, at 8:00 a.m. ET, to discuss its fourth quarter and year-end 2022 financial results. This call will follow the pre-market release of the financial results. Investors can access the live call via the company's investor relations website or dial in using designated numbers. A replay will also be available shortly after the call and for a year thereafter. Amarin is focused on advancing cardiovascular disease management through scientific research and clinical trials, with offices in various locations globally.

Sarissa Capital Management expressed strong concerns regarding Amarin Corporation (NASDAQ: AMRN) leadership, urging shareholders to vote for change in the upcoming meeting. Sarissa claims that current management has significantly reduced shareholder value and mismanaged the company's assets, particularly the valuable drug Vascepa/Vazkepa. With a track record of 39.7% average performance in their portfolio, Sarissa aims to improve Amarin's fortunes. The meeting is scheduled for February 28, 2023, with a voting deadline of February 21, 2023. Sarissa advocates for the removal of Chairman Per Wold-Olsen.

Amarin Corporation (AMRN) is urging shareholders to vote against Sarissa Capital’s proposals ahead of the General Meeting on February 28, 2023. The board emphasizes that Sarissa's attempt to remove the Chairman could harm shareholder value. Leading advisory firms ISS and Glass Lewis support Amarin’s position, endorsing the current board's expertise in crucial pricing and reimbursement negotiations. The board claims Sarissa's nominees lack experience and their record indicates significant negative returns. Amarin asserts a turnaround strategy is underway, focusing on enhancing long-term value for stakeholders.

Sarissa Capital Management has released a presentation urging Amarin shareholders to vote for change during the upcoming shareholder meeting. They emphasize the importance of Vascepa/Vazkepa in reducing cardiovascular events but criticize Amarin's management for poor capital allocation and mismanagement, which they believe is devaluing the asset. Sarissa proposes a slate of qualified candidates who previously turned around a similar company. Shareholders are encouraged to vote 'FOR' Sarissa candidates and the removal of Chairman Per Wold-Olsen before February 21, 2023, to ensure their vote counts for the meeting on February 28, 2023.

Sarissa Capital Management expresses outrage over Amarin Corporation's alleged misleading statements during the proxy contest. Sarissa claims these inaccuracies aim to sway shareholder votes against their nominees. Holding over 25 million shares, Sarissa emphasizes the destruction of shareholder value under Amarin’s current leadership and urges fellow shareholders to support their proposed changes. The voting deadline is set for February 21, 2023, ahead of the General Meeting on February 28, 2023. Shareholders can vote using the blue or white proxy card, ensuring all 'FOR' boxes are marked.